Obsessive - Compulsive DisorderNCT07395453
Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder
An observational study of Obsessive - Compulsive Disorder and Obsessive Compulsive Disorder (OCD), run by Assiut University.
Trial summary
This observational, cross-sectional case-control study evaluates obsessive-compulsive symptoms among adults with substance use disorder compared with a demographically similar control group without substance use disorder. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Obsessive - Compulsive Disorder, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Behavior
- How many people
- 102 participants
- Where
- No sites listed yet
- Study dates
- Mar 2026to Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Adults aged 18-50 years attending the inpatient and outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital, with a diagnosed substance use disorder, and a comparison group of relatives, friends, or hospital workers without substance use disorder. Participants of both sexes who provide informed consent will be assessed once during the recovery (non-intoxication, non-withdrawal) stage using structured clinical interviews, standardized scales for obsessive-compulsive symptoms, psychiatric comorbidity, cognition, and global psychopathology, as well as urine toxicology.
Who may be able to join
- --Adults aged 18-50 years.
- Willing and able to provide informed consent and participate in the study assessments.
- For the case group: patients with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital.
- For the control group: relatives, friends, or hospital workers without substance use disorder, recruited through invitation or advertisement.
Who cannot join
- Severe psychiatric comorbidities such as schizophrenia, major depressive disorder, bipolar disorder, or anorexia nervosa.
- Current intoxication or acute withdrawal state from substances.
- Severe medical conditions including end-stage renal disease, metastatic cancer, severe heart failure, or chronic obstructive pulmonary disease.
- Severe cognitive impairment
About this study
Official title: Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder and Its Correlates
This observational, cross-sectional case-control study evaluates obsessive-compulsive symptoms among adults with substance use disorder compared with a demographically similar control group without substance use disorder. Patients aged 18-50 years attending the addiction management inpatient and outpatient services at Assiut University Hospital, and healthy controls recruited from relatives, friends, and hospital staff, will complete structured clinical interviews, the Yale-Brown Obsessive-Compulsive Scale, and other standardized scales for psychiatric symptoms, cognition, and quality of life. The main objective is to estimate the prevalence and severity of obsessive-compulsive symptoms in substance use disorder and examine their associations with sociodemographic and clinical factors, addiction severity, and quality of life in the recovery stage.
Read the detailed description
Substance use disorders and obsessive-compulsive disorder are chronic, relapsing conditions that share underlying neurobiological mechanisms related to compulsivity and have substantial impact on functioning and quality of life. Clinical experience and prior research suggest that obsessive-compulsive symptoms may be under-recognized among individuals with substance use disorders, where they can worsen psychiatric comorbidity, complicate treatment, and impair recovery.
The current study will recruit 102 adults aged 18-50 years, including 51 patients with a diagnosed substance use disorder (single or polysubstance) from the inpatient and outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital, and 51 control participants without substance use disorder drawn from relatives, friends, and hospital workers. All participants must be in a non-intoxicated, non-withdrawal state and able to provide informed consent; individuals with severe psychiatric disorders (such as schizophrenia, bipolar disorder, major depressive disorder with severe features, or anorexia nervosa), severe medical illness, or marked cognitive impairment will be excluded.
Data collection will include a structured sociodemographic and clinical sheet, brief psychiatric interview, and administration of validated instruments such as the Yale-Brown Obsessive-Compulsive Scale, Obsessive Compulsive Drug Use Scale, Symptom Checklist-90-R, Montreal Cognitive Assessment, and Hamilton scales for anxiety and depression, along with urine analysis for substances. The primary objective is to assess the correlation between obsessive-compulsive symptoms in patients with substance use disorder and both symptom severity and quality of life, while secondary objectives address compulsive aspects of addiction, craving in patients with obsessive-compulsive symptoms, and potential implications for management strategies.
- Conditions
- Obsessive - Compulsive Disorder, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Behavior, Substance Abuse Disorder, Substance Use
- Keywords
- obsessive-compulsive symptoms, substances use disorder
- Medical subject headings
- Compulsive Personality Disorder, Obsessive-Compulsive Disorder, Compulsive Behavior, Substance-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Substance Use Disorder Patients | Adults aged 18-50 years with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at Assiut University Hospital, assessed for obsessive-compulsive symptoms, psychiatric comorbidities, cognition, and quality of life using standardized scales and urine toxicology. | |
| Healthy Control Group | Adults aged 18-50 years without substance use disorder, recruited from relatives, friends, or hospital workers, matched on sociodemographic characteristics where feasible, and assessed with the same clinical and psychometric battery to compare obsessive-compulsive symptoms and related outcomes with the patient group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Severity of Obsessive-Compulsive Symptoms in Patients with Substance Use Disorder Measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score assessing severity of obsessive-compulsive symptoms in patients with substance use disorder. Scale ranges from 0 to 40 points, where higher scores indicate greater severity, assessed once at study enrollment during recovery stage defined as non-intoxication and non-withdrawal.
Measured: Baseline (study enrollment during recovery stage defined as non-intoxication and non-withdrawal); single assessment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study startMar 2026 (estimated)
- Primary completionMar 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obsessive - Compulsive DisorderStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 102 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Esraa Refaat Sayed Ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07395453
- Sponsor's protocol ID
- OCD in substances use disorder
- Status last verified
- Feb 2026
- First submitted
- 4 Dec 2025
- Last updated
- 9 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder and Its Correlates
- ClinicalTrials.gov ID
- NCT07395453
- Acronym / sponsor ID
- OCD in substances use disorder
- Conditions
- Obsessive - Compulsive Disorder, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Behavior, Substance Abuse Disorder, Substance Use
- Keywords
- obsessive-compulsive symptoms, substances use disorder
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 102 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Mar 2026 (estimated)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational, cross-sectional case-control study evaluates obsessive-compulsive symptoms among adults with substance use disorder compared with a demographically similar control group without substance use disorder. Patients aged 18-50 years attending the addiction management inpatient and outpatient services at Assiut University Hospital, and healthy controls recruited from relatives, friends, and hospital staff, will complete structured clinical interviews, the Yale-Brown Obsessive-Compulsive Scale, and other standardized scales for psychiatric symptoms, cognition, and quality of life. The main objective is to estimate the prevalence and severity of obsessive-compulsive symptoms in substance use disorder and examine their associations with sociodemographic and clinical factors, addiction severity, and quality of life in the recovery stage.
Detailed description
Substance use disorders and obsessive-compulsive disorder are chronic, relapsing conditions that share underlying neurobiological mechanisms related to compulsivity and have substantial impact on functioning and quality of life. Clinical experience and prior research suggest that obsessive-compulsive symptoms may be under-recognized among individuals with substance use disorders, where they can worsen psychiatric comorbidity, complicate treatment, and impair recovery.
The current study will recruit 102 adults aged 18-50 years, including 51 patients with a diagnosed substance use disorder (single or polysubstance) from the inpatient and outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital, and 51 control participants without substance use disorder drawn from relatives, friends, and hospital workers. All participants must be in a non-intoxicated, non-withdrawal state and able to provide informed consent; individuals with severe psychiatric disorders (such as schizophrenia, bipolar disorder, major depressive disorder with severe features, or anorexia nervosa), severe medical illness, or marked cognitive impairment will be excluded.
Data collection will include a structured sociodemographic and clinical sheet, brief psychiatric interview, and administration of validated instruments such as the Yale-Brown Obsessive-Compulsive Scale, Obsessive Compulsive Drug Use Scale, Symptom Checklist-90-R, Montreal Cognitive Assessment, and Hamilton scales for anxiety and depression, along with urine analysis for substances. The primary objective is to assess the correlation between obsessive-compulsive symptoms in patients with substance use disorder and both symptom severity and quality of life, while secondary objectives address compulsive aspects of addiction, craving in patients with obsessive-compulsive symptoms, and potential implications for management strategies.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Substance Use Disorder Patients | – | –Adults aged 18-50 years with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at Assiut University Hospital, assessed for obsessive-compulsive symptoms, psychiatric comorbidities, cognition, and quality of life using standardized scales and urine toxicology. |
| Healthy Control Group | – | –Adults aged 18-50 years without substance use disorder, recruited from relatives, friends, or hospital workers, matched on sociodemographic characteristics where feasible, and assessed with the same clinical and psychometric battery to compare obsessive-compulsive symptoms and related outcomes with the patient group. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Adults aged 18-50 years attending the inpatient and outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital, with a diagnosed substance use disorder, and a comparison group of relatives, friends, or hospital workers without substance use disorder. Participants of both sexes who provide informed consent will be assessed once during the recovery (non-intoxication, non-withdrawal) stage using structured clinical interviews, standardized scales for obsessive-compulsive symptoms, psychiatric comorbidity, cognition, and global psychopathology, as well as urine toxicology.
Key inclusion criteria (4 listed)
- --Adults aged 18-50 years.
- Willing and able to provide informed consent and participate in the study assessments.
- For the case group: patients with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital.
- For the control group: relatives, friends, or hospital workers without substance use disorder, recruited through invitation or advertisement.
Key exclusion criteria (4 listed)
- Severe psychiatric comorbidities such as schizophrenia, major depressive disorder, bipolar disorder, or anorexia nervosa.
- Current intoxication or acute withdrawal state from substances.
- Severe medical conditions including end-stage renal disease, metastatic cancer, severe heart failure, or chronic obstructive pulmonary disease.
- Severe cognitive impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Severity of Obsessive-Compulsive Symptoms in Patients with Substance Use Disorder Measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score
Time frame: Baseline (study enrollment during recovery stage defined as non-intoxication and non-withdrawal); single assessment
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score assessing severity of obsessive-compulsive symptoms in patients with substance use disorder. Scale ranges from 0 to 40 points, where higher scores indicate greater severity, assessed once at study enrollment during recovery stage defined as non-intoxication and non-withdrawal.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
Related trials for Obsessive - Compulsive Disorder
Enrolling by invitation
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
Obsessive - Compulsive Disorder, Family Accommodation
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
Recruiting
Focused Ultrasound for Behavioral Health
Depression, Anxiety
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Obsessive - Compulsive Disorder and Obsessive Compulsive Disorder (OCD), run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Severity of Obsessive-Compulsive Symptoms in Patients with Substance Use Disorder Measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score (time frame: Baseline (study enrollment during recovery stage defined as non-intoxication and non-withdrawal); single assessment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.